tirzepatide approval date FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes FDA confirms tirzepatide shortage is

Many patients continue to see meaningful results at 2.4 mg without needing to move to a higher dose

Patients should receive thorough injection training and follow-up assessment to ensure proper technique throughout treatment

Earthquakes below 2.5 magnitude are seldom felt by most people

A 2025 real-world cohort study on the risk of vestibular disorders with semaglutide reported that 15% of patients experienced dizziness after starting treatment, indicating this is not a rare, anecdotal complaint but a pattern clinicians should expect

Poor responders or those with particularly stubborn chronic conditions may benefit from longer treatment phases before breaks

Maybe the most obvious example is the temptations that youll face in everyday life, even if youve tried your best to avoid them